Global
Our Story

Share the latest information

Our Story
News
2023-12-19
Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan
On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.
More
2023-12-19
Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan
On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.
More
2023-11-13
The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!
Recently, Novamab and the team of Professor Zhang Xuyao/Ju Dianwen from the School of Pharmacy, Fudan University, jointly reported that the nanobody-drug conjugate (NDC) molecule targeting TROP2 has p
More
2023-09-26
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
More
2023-09-18
CDE approves IND application for LQ036 in the treatment of COPD
CDE approves IND application for LQ036 in the treatment of COPD ◇———A global leading Biotech in the  R&D of innovative Nanobody drugs———◇
More
2023-07-04
CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum
CEO of Luoqi Biotechnology delivers a speech at the ACCESS CHINA Pharmaceuticals China Boston ForumA leading global enterprise in the research and development of innovative nano antibody drugsThe offl
More
2023-06-28
LQ036 IND application for COPD accepted by CDE
On June 27, 2023, Shanghai Novamab Biological Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biological") announced that the IND application for COPD indication of LQ036 (LQ036
More
2023-05-25
Novamab presented the latest progress of 3 core assets at the ATS 2023 conference
On May 21, 2023, Dr. Wan Yakun, founder and chairman of Shanghai NovamabBiomedical Technology Co., Ltd., was invited to participate in the 2023 American Thoracic Society International Conference/Annua
More
2023-05-12
Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023
A leading global enterprise in the research and development of innovative nano antibody drugsRecently, Dr. Wan Yakun, founder and chairman of Shanghai Novamab Biomedical Technology Co., Ltd., was invi
More
2023-04-06
Novamab:Systematic Opportunities for Antibody Inhalation Administration
In 2022, among the top 20 best-selling drugs in the world, 8 are macromolecular drugs, and the proportion will be higher if COVID-19 is excluded. The two best-selling drugs Humira and Keytruda are ant
More
2023-01-14
洛启生物 祝您元旦快乐
描述为占位文字请客户提供描述为占位文字请客户提供,描述为占位文字请客户提供描述为占位文字请客户提供...
More
Total 46 12345